M&A / Deals Gan & Lee and JW Pharmaceutical agree on bofanglutide commercialisation Pharmaceutical Business ReviewBofanglutide is a bi-weekly glucagon-like peptide-1 receptor agonist (GLP-1RA) discovered and developed by Gan Lee.M&A / DealsMetabolic & GLP-1Read full story pharminent April 10, 2026 (Last updated: April 10, 2026) Pharmaceutical Business Review Bofanglutide is a bi-weekly glucagon-like peptide-1 receptor agonist (GLP-1RA) discovered and developed by Gan Lee. M&A / DealsMetabolic & GLP-1Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Precision Medicine in Early Oncology Trials: Biomarkers as Strategic DriversNext: Roche and C4 Therapeutics to advance degrader-antibody conjugates research Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
